Tariffs should not influence decisions at Indian drug companies, Cipla's top executive said on Friday, as the industry braces ...

Discover the Cipla Stock Liveblog, your go-to destination for real-time updates and comprehensive analysis of a ...

Welcome to the Cipla Stock Liveblog, your go-to platform for real-time updates and analysis on a top-performing stock. Stay ...

Indian equity markets are closed today, Friday, March 14, in observance of Holi, the vibrant festival of colors celebrated ...

Shares of Cipla are set to be in focus on Friday after the company received final approval from the U.S. Food and Drug Administration for its New Drug Application (NDA) for Nilotinib capsules ...

We would like most of the manufacturing to be centric in locations where it is most economic. Looking at every country's ...

India, often dubbed the "pharmacy of the world", is among the top exporters to the U.S., especially for cheaper versions of ...

Cipla Limited is an Indian multinational pharmaceutical company that is headquartered in Mumbai, Maharashtra. The company is primarily known for producing generic drugs for various therapeutic uses.

Umang Vohra to Nimura: "In the case of tariff barriers, generics companies are likely to be more selective, focusing on high-value opportunities including 'first to file'." The Managing Director ...

For Monday, an analyst from a domestic brokerage assigned 'Buy/Sell' calls on Kfin Technologies, MOFSL and Cipla shares.

Stay updated with the latest stock market news and live updates. Get real-time insights on Sensex Today, Nifty Live, stock market today, IPO news and more on Business Standard.

MUMBAI/BENGALURU, Feb 28 (Reuters) - Tariffs should not influence decisions at Indian drug companies, Cipla's (CIPL.NS), opens new tab top executive said on Friday, as the industry braces for U.S ...